Countries that use a NICE-like reimbursement system probably won’t cover TAF at all. In the US, payers will employ the usual roadblocks such as higher copays, step edits, and prior-authorization requirements to restrict TAF to those who really need it.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”